siloraner

Siloraner is a synthetic chemical compound primarily used as a non-steroidal anti-inflammatory drug (NSAID) in veterinary medicine. It belongs to the class of drugs known as arylpropionic acids, which are commonly employed to reduce inflammation, pain, and fever. Siloraner is particularly notable for its dual mechanism of action, targeting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which play key roles in the production of prostaglandins—molecules involved in inflammation and pain signaling.

The drug was developed by Zoetis, a global animal health company, and was first approved for use in the United States in 2016. Siloraner is marketed under the brand name **Artramis** and is specifically indicated for the management of osteoarthritis pain in dogs. Its formulation combines siloraner with meloxicam, another NSAID, to provide extended-release effects, allowing for once-monthly administration via an injectable suspension. This extended-release mechanism helps maintain therapeutic drug levels over time, reducing the frequency of dosing compared to traditional NSAIDs.

Clinical studies have demonstrated siloraner’s efficacy in improving mobility and reducing signs of osteoarthritis in dogs, such as lameness and stiffness. Like other NSAIDs, siloraner carries potential side effects, including gastrointestinal irritation, kidney toxicity, and an increased risk of bleeding. Due to these risks, its use is generally reserved for dogs diagnosed with osteoarthritis, and veterinarians closely monitor patients receiving the treatment.

Siloraner’s development reflects ongoing advancements in veterinary pharmacology aimed at improving the quality of life for animals suffering from chronic pain conditions. Its approval marked a milestone in the availability of long-acting, dual-action NSAIDs for canine osteoarthritis management.